The U.S. Food and Drug Administration yesterday asked Endo Pharmaceuticals to remove its opioid pain medication Opana ER from the market, citing the potential for the reformulated drug to be abused. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
The AHA today responded to an HHS request for input from health care providers and other stakeholders on ensuring legitimate access to controlled substances…
Headline
The Centers for Disease Control and Prevention has partnered with Medscape to offer free online training on its recommendations for vaccinating homeless people…
Headline
The HPV vaccine could prevent an estimated 92% of cancers caused by the human papillomavirus in the United States, according to a new study by the Centers for…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response will provide $23 million for Merck to produce…
Headline
The Food and Drug Administration yesterday approved a new antibiotic to treat adults with community-acquired bacterial pneumonia.
Headline
The number of U.S. hospitals with an antibiotic stewardship program that meets all core elements recommended by the Centers for Disease Control and Prevention…